CUL 주식 개요 는 자회사와 함께 미국에서 부인과 질환에 대한 비침습적 AI 기반 진단 테스트를 발굴, 개발 및 상용화하는 기업입니다. 자세한 내용
보상 위험 분석 + 2 더 많은 위험
모든 위험 점검 보기 생각, 링크 및 회사 내러티브를 캡처하세요.
Aspira Women's Health Inc. 경쟁사 가격 내역 및 성능
다음에 대한 주가 최고가, 최저가 및 변동 요약 Aspira Women's Health 과거 주가 현재 주가 US$0.31 52주 최고치 US$4.80 52주 최저치 US$0.28 베타 1.42 1개월 변경 -48.00% 3개월 변경 사항 -58.12% 1년 변경 사항 -93.39% 3년 변화 -97.81% 5년 변화 -96.99% IPO 이후 변화 -99.99%
최근 뉴스 및 업데이트 Aspira Women's Health Inc. Appoints James Crawford as Principal Accounting Officer
Aspira Women's Health Inc. Appoints Mike Buhle as SVP of Commercial Operations Jan 10 Aspira Women's Health Inc. has filed a Follow-on Equity Offering. Jan 09
Aspira Women's Health Announces Resignation of John Kallassy as Interim Chief Financial Officer, Effective January 10, 2025 Jan 08
Aspira Women's Health Inc. Provides Nasdaq MVLS Non-Compliance Update Jan 01 Aspira Women's Health Inc. Announces Departure of Nicole Sandford as Board Member 더 많은 업데이트 보기 Aspira Women's Health Inc. Appoints James Crawford as Principal Accounting Officer
Aspira Women's Health Inc. Appoints Mike Buhle as SVP of Commercial Operations Jan 10 Aspira Women's Health Inc. has filed a Follow-on Equity Offering. Jan 09
Aspira Women's Health Announces Resignation of John Kallassy as Interim Chief Financial Officer, Effective January 10, 2025 Jan 08
Aspira Women's Health Inc. Provides Nasdaq MVLS Non-Compliance Update Jan 01 Aspira Women's Health Inc. Announces Departure of Nicole Sandford as Board Member
Aspira Women's Health Inc. Successfully Reaches the First Milestone of the Advanced Research Projects Agency for Health $10 Million Award Dec 04 Aspira Women's Health Inc. announced delayed 10-Q filing Nov 15
Aspira Women's Health Inc. to Report Nine Months, 2024 Results on Nov 14, 2024 Nov 04 Aspira Women's Health Inc. Announces Its Selection Receive $10 Million Award from Advanced Research Projects Agency for Health’s Sprint for Women's Health Oct 24
Aspira Women's Health Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement Oct 19
Second quarter 2024 earnings released: US$0.28 loss per share (vs US$0.28 loss in 2Q 2023) Aug 13
Aspira Women's Health Inc. Appoints John Kallassy as Interim Chief Financial Officer, Effective August 15, 2024 Aug 13
New major risk - Shareholder dilution Aug 05 Aspira Women's Health Inc. has filed a Follow-on Equity Offering in the amount of $4.45 million. Aug 03
Aspira Women's Health Inc. to Report Q2, 2024 Results on Aug 12, 2024 Aug 01
Aspira Women’s Health Inc Appoints John Ragard to Its Board of Directors Jul 29
New major risk - Shareholder dilution Jul 14 Aspira Women's Health Inc. announced that it has received $1.910249 million in funding Jul 10
Aspira Women’s Health Receives Written Notice from Nasdaq Due to Non-Compliance with the Minimum of $35 Million Market Value of Listed Securities Requirement Pursuant to Nasdaq Listing Rule 5550(b)(2) Jul 06 Aspira Women's Health Inc. announced that it expects to receive $1.935051 million in funding Jul 02
First quarter 2024 earnings released: US$0.39 loss per share (vs US$0.73 loss in 1Q 2023) May 17
Aspira Women's Health Inc. to Report Q1, 2024 Results on May 15, 2024 May 10
Aspira Women's Health Inc. Enhances Its Commercial Offering with the Formal Launch of Longitudinal Monitoring Feature of Ovawatch May 03
Aspira Women's Health Inc. Announces Minh Merchant Resigns as General Counsel, Chief Compliance Officer, and Corporate Secretary, Effective May 6, 2024 Apr 28
Aspira Women's Health Inc., Annual General Meeting, May 13, 2024 Apr 02
Full year 2023 earnings released: US$1.81 loss per share (vs US$3.85 loss in FY 2022) Mar 29
Aspira Women's Health Inc. Announces Executive Changes Mar 20
Aspira Women's Health Inc. to Report Q4, 2023 Results on Mar 28, 2024 Mar 12
High number of new and inexperienced directors Feb 05 Aspira Women's Health Inc. has filed a Follow-on Equity Offering in the amount of $5.50031 million. Jan 26
Aspira Women's Health Inc. Announces Resignation of Veronica G.H. Jordan from the Board of Directors Dec 28
Aspira Women's Health Provides Development Update on its Portfolio of Noninvasive Tests for Endometriosis Dec 06
Aspira Women's Health Receives Final Crosswalk Pricing Determination from the Centers for Medicare & Medicaid Services (CMS) Nov 29
Aspira Women's Health Receives Final Crosswalk Pricing Determination from the Centers for Medicare & Medicaid Services (CMS) Nov 28
Aspira Women's Health Inc. to Report Q3, 2023 Results on Nov 13, 2023 Nov 02
Aspira Women's Health Sees Poster on its MiRNA-Based Ovarian Cancer Test Presented at the AACR Special Conference in Cancer Research Oct 26
Aspira Women's Health Establishes A New Clinical Advisory Board Oct 24
Aspira Women’s Health Regains Nasdaq Compliance Sep 14
Aspira Women’s Health Announces Executive Changes Sep 12
Aspira Women’s Health Announces Michelle Snider as Senior Vice President, Commercial Strategy and Operations Aug 29
Aspira Women’S Health Inc. Announces Resignation of Ryan Phan as Chief Scientific and Operating Officer, Effective September 15, 2023 Aug 10
Aspira Women's Health Inc. to Report Q2, 2023 Results on Aug 14, 2023 Aug 01
Aspira Women’s Health Receives Written Notice from the Listing Qualifications Staff of the Nasdaq Stock Market Jul 16
Aspira Women's Health Inc. Appoints Dr. Winfred Parnell to Its Board of Directors, Member of Nominating and Corporate Governance Committee Jun 07
Aspira Women's Health Inc. Appoints Dr. Winfred Parnell to Its Board of Directors Jun 06
Aspira Women's Health Inc. Announces Chief Financial Officer Changes, Effective June 15, 2023 May 17
First quarter 2023 earnings released: US$0.73 loss per share (vs US$1.24 loss in 1Q 2022) May 13
Aspira Women's Health Inc. Appoints Three New Members to Its Board of Directors May 10
Full year 2022 earnings released: US$0.23 loss per share (vs US$0.28 loss in FY 2021) Mar 24
Aspira Women’s Health Inc. Announces Publication of Real-World Data Validating Use of OvaWatch for Management of Adnexal Masses Jan 07
Aspira Women's Health Inc. Announces Executive Changes Dec 24 Aspira Women's Health Receives A Written Notice from Nasdaq
Aspira Women's Health Inc. Announces the Commercial Launch of OvaWatch Dec 02
Third quarter 2022 earnings released: US$0.039 loss per share (vs US$0.087 loss in 3Q 2021) Nov 16
Third quarter 2022 earnings released: US$0.039 loss per share (vs US$0.087 loss in 3Q 2021) Nov 12
Aspira Women's Health Inc. to Report Q3, 2022 Results on Nov 10, 2022 Nov 02
Aspira Women's Health Inc. Announces Publication of Its Second-Generation Multivariate Index Assay, Overa®, in the Detection of Cancer in Filipino Women Sep 13 Aspira Women's Health Inc. has completed a Follow-on Equity Offering. Aug 24
Second quarter 2022 earnings released: US$0.073 loss per share (vs US$0.063 loss in 2Q 2021) Aug 12
Aspira Women's Health Inc. to Report Q2, 2022 Results on Aug 10, 2022 Aug 02
Aspira Women's Health Inc. Announces Board Appointments Jun 24
Aspira Women’s Health Inc. Receives A Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market Jun 03
President recently bought €72k worth of stock May 19
First quarter 2022 earnings released: US$0.083 loss per share (vs US$0.054 loss in 1Q 2021) May 13
Aspira Women's Health Inc. Appoints Ryan Phan, Ph.D. as Chief Operating and Scientific Officer May 13 Aspira Women's Health Inc., Annual General Meeting, Jun 23, 2022
High number of new directors Mar 29
Aspira Women's Health Inc. Appoints Valerie B. Palmieri as Its Executive Chairperson Mar 03
Aspira Women’S Health Announces Appointment of Celeste Fralick to Its Board of Directors Mar 01 Aspira Women's Health Inc. Appoints Nicole Sandford as Chief Executive Officer, Effective March 1, 2022
Aspira Women’s Health, Inc. Name Mr. Michael Newton as Head of Sales and Marketing Feb 24
Third quarter 2021 earnings released: US$0.087 loss per share (vs US$0.042 loss in 3Q 2020) Nov 11
Second quarter 2021 earnings released: US$0.063 loss per share (vs US$0.039 loss in 2Q 2020) Aug 13 주주 수익률 CUL DE Medical Equipment DE 마켓 7D -11.4% 2.9% 1.9% 1Y -93.4% -1.0% 15.1%
전체 주주 수익률 보기
수익률 대 산업: CUL 지난 1년 동안 -1 %를 반환한 German Medical Equipment 업계보다 저조한 성과를 냈습니다.
수익률 대 시장: CUL 지난 1년 동안 15.1 %를 반환한 German 시장보다 저조한 성과를 냈습니다.
가격 변동성 Is CUL's price volatile compared to industry and market? CUL volatility CUL Average Weekly Movement 16.4% Medical Equipment Industry Average Movement 6.3% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.4%
안정적인 주가: CUL 의 주가는 지난 3개월 동안 German 시장과 비교해 변동성이 컸습니다.
시간에 따른 변동성: CUL 의 주간 변동성 ( 16% )은 지난 1년 동안 안정적이었지만 여전히 German 의 75%보다 높습니다. 주식.
회사 소개 는 자회사와 함께 미국에서 부인과 질환에 대한 비침습적 AI 기반 진단 테스트를 발굴, 개발 및 상용화하는 회사입니다. 이 회사의 제품에는 난소 부속 종괴가 있는 여성의 악성 가능성을 평가하는 정성 혈청 검사 Ova1Plus, Ova1의 높은 민감도를 유지하기 위한 바이오마커 검사 Overa, 불확정 또는 양성 부속 종괴가 있다고 생각되는 모든 여성의 악성 위험에 대한 초기 임상 평가를 지원하기 위해 실험실에서 개발한 검사 OvaWatch가 있습니다. 또한 부속 종괴가 있는 여성의 난소암 위험을 평가하기 위해 혈청 단백질, 임상 데이터 및 miRNA를 결합한 다중 마커 테스트인 OvaMDx, 난소 자궁내막종을 식별하도록 설계된 단백질 바이오마커인 EndoCheck, 자궁내막증 식별을 위한 EndoMDx를 개발 중입니다.
자세히 보기 Aspira Women's Health Inc. 기본 사항 요약 Aspira Women's Health 의 수익과 매출은 시가총액과 어떻게 비교하나요? CUL 기본 통계 시가총액 €6.06m 수익(TTM ) -€14.27m 수익(TTM ) €8.65m
수익 및 수익 최신 수익 보고서의 주요 수익성 통계(TTM) CUL 손익 계산서(TTM ) 수익 US$8.96m 수익 비용 US$3.75m 총 이익 US$5.21m 기타 비용 US$20.00m 수익 -US$14.79m
주당 순이익(EPS) -0.89 총 마진 58.12% 순이익 마진 -165.07% 부채/자본 비율 -62.0%
CUL 의 장기적인 성과는 어땠나요?
과거 실적 및 비교 보기
기업 분석 및 재무 데이터 현황 데이터 마지막 업데이트(UTC 시간) 기업 분석 2025/02/02 03:05 장 마감 주가 2025/01/31 00:00 수익 2024/09/30 연간 수익 2023/12/31
데이터 소스 기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.
패키지 데이터 기간 미국 소스 예시 * 회사 재무 10년 애널리스트 컨센서스 추정치 +3년 시장 가격 30년 소유권 10년 관리 10년 주요 개발 사항 10년
* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.
명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.
분석 모델 및 눈송이 이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.
Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.
산업 및 부문 메트릭 업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.
애널리스트 출처 Aspira Women's Health Inc. 10 애널리스트 중 1 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.
분석가 교육기관 James Molloy Alliance Global Partners Benjamin Haynor Alliance Global Partners Laura McGuigan B. Riley Securities, Inc.
7 더 많은 분석가 보기 
